ABSTRACT Lower airway responses to nebulised bronchodilators were studied in 18 chronically or recurrently wheezy infants, aged 3-15 months, by means of partial forced expiratory flow-volume manoeuvres performed with an inflatable jacket. Maximum flow at functional residual capacity (FRC) (VmaxFRc) was used as the index of intrathoracic airways function. Peak expiratory flow rate was also measured. Baseline airways resistance and lung volume were determined during quiet breathing in an infant whole body plethysmograph. Measurements were made on separate days before 'and after nebulised salbutamol 25 mg with nebulised saline as control. The results were paradoxical: there was no change in VmaxFRc after saline, but a significant decline in VmaxFRc was found after salbutamol. Peak expiratory flow remained unchanged. These observations suggest that under conditions of forced expiration intrathoracic airways function may be further impaired by nebulised bronchodilator treatment in wheezy infants. When nebulised bronchodilator drugs are used to treat severe airways obstruction in infancy, careful monitoring is essential.
It is now widely believed that wheezy infants, in constrast with older children, do not respond to either of the two generally available classes of bronchodilator drugs, P2 selective sympathomimetic agents and anticholinergic, antimuscarinic agents. Most physiological measurements'-' and clinical trials34 have shown no significant effect, although a clinical benefit has been claimed for combination treatment with a 2 sympathomimetic agent and a corticosteroid in acute bronchiolitis. 5 The many reasons that have been put forward for the apparent lack of response include inadequate airway smooth muscle, insufficient or ineffective P receptors, and inappropriate airway pathophysiology. 6 One additional factor that has not been taken into account is the relative contribution of the upper airways to airways obstruction in wheezy infants. In the past, measurements of airways function in wheezy infants have been made during sleep, when it is reasonable to assume nasal breathing, and have therefore provided an overall value for upper and lower airways combined. Normally the nasal passages account for about half of the overall airways resistance in caucasian infants,7 while the glottis accounts for a further important proportion, especially in the presence of obstructive airways disease.89 Wheezy infants commonly suffer from upper airway obstruction, and so the upper airways resistance may contribute very considerably and very variably to measured values of airways resistance, masking any possible bronchial effects of inhaled drugs and possibly giving misleading results since these drugs also act on the upper airway.'0 Forced expiratory flow-volume curves in older children and adults provide information about intrathoracic airways function independently of quite wide variations in glottic and nasal obstruction. A technique has recently been described for obtaining flow-volume curves during tidal breathing in sleeping infants, in which forced expiration is effected by thoracoabdominal compression. " 12 We have applied this technique to study the effect of a single nebulised dose of salbutamol on intrathoracic airway function in infants with chronic or recurrent wheeze.
Methods

PATIENTS
A total of 18 infants aged 3-15 months completed 86
Paradoxical response to nebulised salbutamol in wheezy infants both study days. All had a history of recurrent wheezing, but none had symptoms at the time of testing. Ten had a first degree relative with atopic disease; three had had acute bronchiolitis requiring hospital admission (and in two cases mechanical ventilation) at the onset of their chronic chest disorder, and three had been mechanically ventilated in the neonatal period for neonatal respiratory distress syndrome. None had evidence of cystic fibrosis, recurrent aspiration, or congenital abnormalities of the lungs or heart. Infants were studied after chloral sedation (100mg/kg orally) in an interval between acute attacks of wheeze and in the absence of appreciable nasal symptoms. The studies formed part of the clinical evaluation, for which their parents' consent was obtained.
LUNG FUNCTION TESTS
Baseline plethysmographic measurements of end expiratory thoracic gas volume (TGV) and initial inspiratory airways resistance (Raw) from pressureflow curves'3 14 were made by methods After we had obtained baseline flow-volume curves and performed plethysmography, a control solution of nebulised normal saline (2-5ml) was given by Turrent nebuliser (Medic-Aid), with an airflow of 61 min-. The nebuliser output was measured as 0 21 ml min-. Several flow-volume curves were collected after 10 minutes. Salbutamol (2-5 mg in 2-5 ml saline) was then given and full lung function tests were repeated after a 15 minute interval. Because of the duration of a full set of observations (up to two hours), some infants awoke before completion, leading to incomplete data or, on occasion, causing the investigations to be abandoned. In particular, reliable measurements of TGV and airway resistance were obtained at the end of the study in only 10 patients.
ANALYSIS
Paired t tests were used to assess the overall effect of salbutamol on the physiological variables. The significance of individual responses to salbutamol was assessed by reference to the confidence limits for VmaxFRc and PEF determined from the baseline measurements for each individual.
Results
Initial lung function values confirmed the presence of appreciable airways obstruction (table 1) . In particular the mean value of sRaw was 3-7 times the normal value of 35 cm H20.s while VmaxFRc and PEF were reduced to 36% and 65% of their predicted values.'2 Only four infants had a normal value of sRaw before study, and all of these were in the upper half of the normal range. After nebulised saline there was no significant mean change in VmaxFRC or PEF (table 2) . Nebulised salbutamol produced a significant fall in mean VmaxFRc (t = 2-35) but no change in mean PEF or in sRaw (table 2) .
Examination of the individual results showed that most infants had a significant decline in VmaxFRc both after saline and after salbutamol (table 3, fig 1) . There were no notable trends in the PEF response (table 3) . In conjunction with change in the measured values of VmaxFRC, there were changes in the shape of PEFV curves after salbutamol. A' decline in VmaxFRc was associated with increased convexity of the curve towards the axes (fig 2a) . With improvement in VmaxFRc the PEFV curve tended to become straighter and to shift away from the tidal flow-volume curve (fig 2b) .
There were no differences in the responses between the eight infants over 8 months and those under 8 months, or between those with and those without a history of bronchiolitis or of neonatal mechanical ventilation or a family history of atopic disease.
Five out of 72 sets of flow-volume data were based on less than three technically satisfactory observations. Technical problems during the flow-volume procedure, which led to unsatisfactory curves, included irregular breathing, glottic closure during expiration, and tidal and maximum flow-volume 88 In support of the numerical analysis of flow-volume curves, there was a corresponding change in the shape of the curves (fig 2) . The change in shape that accompanied a fall in VmaxFRc (fig2a) makes it unlikely that inspiratory effort against the jacket caused the decline in VmaxFRc. If this had been the case, the terminal segment of the PEFV curve would have become concave to the axes, as we have previously found in curves truncated by inspiratory effort.'2 A reduction in forced expiratory flow rate after bronchodilator treatment, without an increase in airways resistance during quiet breathing, has been previously found in other chronic airway disorders.'9 21
The explanation for this depends on the relative effects of bronchodilator drugs on airway compliance (by altering smooth muscle tone) and on airway calibre. An increase in airway compliance due to a decrease in airway smooth muscle tone will tend to diminish maximum flow rates at low lung volumes, since flow is limited by (among other factors) the properties of the airway wall.22 If intrathoracic airway calibre is not coincidentally improved by bronchodilator treatment, then the net effect of these drugs will be little or no improvement in overall airway resistance or lung volume during quiet breathing, but a decline in end expiratory flow rates during forced expiration. We have recently shown the opposite effect in response to low concentrations of the bronchoconstrictor agent histamine in some wheezy infants.23 There the lowest concentrations of nebulised histamine occasionally caused a rise in VmaXFRC. Higher concentrations had the more expected effect, with a fall in VmaxFRc. In this case a fall in airway compliance, without change in calibre, could provide the explanation for the paradoxical response to low histamine concentrations.
Although we have found PEF to be a reproducible index of forced flow in infants,' 2 Prendiville, Green, Silverman occur in older subjects too, usually rapid bronchodilatation more than compensates for this. It may be desirable to monitor transcutaneous Po2 or oxygen saturation during bronchodilator administration in ill wheezy infants, and there may be a case for giving oxygen to avoid adverse effects in the event of a paradoxical response to the bronchodilator.
The results obtained with the PEFV manoeuvre may have important implications for the physiological assessment of bronchoactive agents in infants. Plethysmographic measurements of lung volume and Raw are technically difficult and may not provide clinically relevant data.18 Not only is Raw affected by nasal obstruction, but its measurement under conditions of sedation and quiet breathing does not mimic the conditions that are found during tachypnoea and forced breathing in an acutely wheezy infant. The PEFV manoeuvre goes some way towards replicating the clinical situation, and as we have shown, may give contrasting results.
